These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32710435)

  • 1. Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.
    Dhaese S; Heffernan A; Liu D; Abdul-Aziz MH; Stove V; Tam VH; Lipman J; Roberts JA; De Waele JJ
    Clin Pharmacokinet; 2020 Oct; 59(10):1237-1250. PubMed ID: 32710435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
    Abdul-Aziz MH; Portunato F; Roberts JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.
    Lee YR; Miller PD; Alzghari SK; Blanco DD; Hager JD; Kuntz KS
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):155-170. PubMed ID: 29027128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
    Thabit AK; Hobbs ALV; Guzman OE; Shea KM
    Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
    Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
    Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
    Mohd Hafiz AA; Staatz CE; Kirkpatrick CM; Lipman J; Roberts JA
    Minerva Anestesiol; 2012 Jan; 78(1):94-104. PubMed ID: 21730935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews.
    Thabet P; Joshi A; MacDonald E; Hutton B; Cheng W; Stevens A; Kanji S
    PLoS One; 2021; 16(1):e0244966. PubMed ID: 33481817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
    Roberts JA; Paul SK; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Clin Infect Dis; 2014 Apr; 58(8):1072-83. PubMed ID: 24429437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-lactam antibiotics: is continuous infusion the preferred method of administration?
    Vondracek TG
    Ann Pharmacother; 1995 Apr; 29(4):415-24. PubMed ID: 7633021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.
    Tamma PD; Putcha N; Suh YD; Van Arendonk KJ; Rinke ML
    BMC Infect Dis; 2011 Jun; 11():181. PubMed ID: 21696619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics.
    MacGowan A
    Curr Opin Pharmacol; 2011 Oct; 11(5):470-6. PubMed ID: 21862409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
    Roberts JA; Paratz J; Paratz E; Krueger WA; Lipman J
    Int J Antimicrob Agents; 2007 Jul; 30(1):11-8. PubMed ID: 17442541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.
    Gatti M; Cojutti PG; Pea F
    Crit Care; 2024 Apr; 28(1):123. PubMed ID: 38627763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.
    Assefa GM; Roberts JA; Mohammed SA; Sime FB
    J Antimicrob Chemother; 2024 May; 79(5):946-958. PubMed ID: 38459763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
    Gonçalves-Pereira J; Póvoa P
    Crit Care; 2011; 15(5):R206. PubMed ID: 21914174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.